During the last session, Editas Medicine Inc. (NASDAQ:EDIT)’s traded shares were 3.1 million, with the beta value of the company hitting 2.04. At the end of the trading day, the stock’s price was $18.69, reflecting an intraday gain of 13.41% or $2.21. The 52-week high for the EDIT share is $73.03, that puts it down -290.74 from that peak though still a striking 48.69% gain since the share price plummeted to a 52-week low of $9.59. The company’s market capitalization is $1.36B, and the average intraday trading volume over the past 10 days was 1.56 million shares, and the average trade volume was 1.75 million shares over the past three months.
Editas Medicine Inc. (EDIT) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 2.60. EDIT has a Sell rating from 3 analyst(s) out of 17 analysts who have looked at this stock. 7 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.82.
Editas Medicine Inc. (NASDAQ:EDIT) trade information
Editas Medicine Inc. (EDIT) registered a 13.41% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 13.41% in intraday trading to $18.69 this Wednesday, 08/03/22, hitting a weekly high. The stock’s 5-day price performance is 10.99%, and it has moved by 28.45% in 30 days. Based on these gigs, the overall price performance for the year is -55.62%. The short interest in Editas Medicine Inc. (NASDAQ:EDIT) is 16.38 million shares and it means that shorts have 7.93 day(s) to cover.
The consensus price target of analysts on Wall Street is $31.07, which implies an increase of 39.85% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8.00 and $80.00 respectively. As a result, EDIT is trading at a discount of -328.04% off the target high and 57.2% off the low.
Editas Medicine Inc. (EDIT) estimates and forecasts
Statistics show that Editas Medicine Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Editas Medicine Inc. (EDIT) shares have gone down -5.08% during the last six months, with a year-to-date growth rate less than the industry average at -19.65% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -1.20% this quarter and then drop -50.90% in the quarter after that. In the rating firms’ projections, revenue will decrease -16.30% compared to the previous financial year.
Revenue for the current quarter is expected to be $4.29 million as predicted by 13 analyst(s). Meanwhile, a consensus of 13 analyst(s) estimates revenue growth to $4.69 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $379k and $6.2 million respectively. In this case, analysts expect current quarter sales to grow by 1,031.90% and then drop by -24.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.20%. While earnings are projected to return -43.90% in 2022.
Editas Medicine Inc. is due to release its next quarterly earnings between February 23 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Editas Medicine Inc. (NASDAQ:EDIT)’s Major holders
Editas Medicine Inc. insiders own 0.49% of total outstanding shares while institutional holders control 70.13%, with the float percentage being 70.47%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 359 institutions own stock in it. As of Mar 30, 2022, the company held over 6.88 million shares (or 10.02% of all shares), a total value of $130.79 million in shares.
The next largest institutional holding, with 6.28 million shares, is of Blackrock Inc.’s that is approximately 9.14% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $119.36 million.
Also, the Mutual Funds coming in first place with the largest holdings of Editas Medicine Inc. (EDIT) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Jun 29, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 6.43 million shares. This amounts to just over 9.37 percent of the company’s overall shares, with a $76.11 million market value. The same data shows that the other fund manager holds slightly less at 1.98 million, or about 2.89% of the stock, which is worth about $37.67 million.